Workflow
ACMSH(688082)
icon
Search documents
盛美上海1月22日获融资买入1.56亿元,融资余额9.14亿元
Xin Lang Cai Jing· 2026-01-23 01:32
Group 1: Company Performance - As of September 30, 2025, the company achieved operating revenue of 5.146 billion yuan, representing a year-on-year growth of 29.42% [2] - The net profit attributable to the parent company for the same period was 1.266 billion yuan, showing a year-on-year increase of 66.99% [2] - Cumulative cash dividends since the company's A-share listing amount to 723 million yuan [3] Group 2: Shareholder and Market Activity - As of January 22, 2023, the company experienced a financing buy-in of 156 million yuan, with a net financing buy of 34.96 million yuan [1] - The total financing and securities lending balance reached 917 million yuan, with the financing balance accounting for 1.02% of the circulating market value, indicating a high level compared to the past year [1] - The number of shareholders increased to 21,700, a rise of 85.89% compared to the previous period, while the average circulating shares per person decreased by 46.20% to 20,098 shares [2] Group 3: Institutional Holdings - As of September 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 5.0576 million shares, a decrease of 978,700 shares from the previous period [3] - Other notable institutional shareholders include Huaxia SSE STAR 50 ETF, which decreased its holdings by 1.7735 million shares, and Nuoan Growth Mixed A, which reduced its holdings by 754,100 shares [3]
今日晚间重要公告抢先看——兆易创新预计2025年净利同比预增46%左右;白银有色称股票价格短期涨幅较大 存在交易风险
Jin Rong Jie· 2026-01-22 13:26
Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]
盛美上海:2025年营业收入66.8亿元–68.8亿元,同比增长18.91%–22.47%
Xin Lang Cai Jing· 2026-01-22 11:09
盛美上海1月22日公告,预计2025年度实现营业收入668,000.00万元–688,000.00万元,同比增长18.91%– 22.47%,上年同期营业收入561,774.04万元。综合近年来的业务发展趋势,以及目前的订单等多方面情 况,公司预计2026年全年的营业收入将在人民币82.00亿元至88.00亿元之间。 ...
盛美上海:预计2026年营业收入将在82亿元至88亿元之间
Mei Ri Jing Ji Xin Wen· 2026-01-22 10:30
每经AI快讯,1月22日,盛美上海发布2025年度业绩预告,预计营业收入为66.8亿元~68.8亿元,比上年 同期增长18.91%~22.47%。报告期内,全球半导体市场需求强劲,公司凭借技术差异化优势,持续推进 销售交付与调试验收,产品平台化进展顺利,客户全球化拓展成效显著,新客户开发取得突破,市场认 可度不断提升,推动营业收入稳步增长。综合近年来的业务发展趋势,以及目前的订单等多方面情况, 公司预计2026年全年的营业收入将在82亿元至88亿元之间。 ...
盛美上海:预计2026年营业收入将在82亿元-88亿元之间
Di Yi Cai Jing· 2026-01-22 10:30
Core Viewpoint - The company expects its operating revenue for 2025 to be between RMB 6.68 billion and RMB 6.88 billion, representing a year-on-year growth of 18.91% to 22.47% [1] - For the year 2026, the company anticipates its total operating revenue to be between RMB 8.20 billion and RMB 8.80 billion [1] Summary by Category - **2025 Revenue Forecast** - The projected operating revenue for 2025 is estimated to be between RMB 6.68 billion and RMB 6.88 billion [1] - This forecast indicates a growth rate of 18.91% to 22.47% compared to the previous year [1] - **2026 Revenue Forecast** - The company forecasts its total operating revenue for 2026 to be in the range of RMB 8.20 billion to RMB 8.80 billion [1]
盛美上海:2025年营收预增近两成,2026年预计达82 - 88亿元
Xin Lang Cai Jing· 2026-01-22 10:30
盛美上海公告称,2025年营收预计66.80 - 68.80亿元,同比增长18.91% - 22.47%。主要因全球半导体行 业发展活跃,公司技术、产品和市场三方面优势促进业绩增长。公司预计2026年营收82.00 - 88.00亿 元。控股股东ACMResearch已披露其2025及2026业绩预测,数据因准则等差异与公司不可直接对比。公 司提醒,2025业绩未审计,2026预测有不确定性,投资者应注意风险。 ...
盛美上海(688082) - 关于自愿披露2025年度经营业绩及2026年度经营业绩预测的公告
2026-01-22 10:30
证券代码:688082 证券简称:盛美上海 公告编号:2026-002 盛美半导体设备(上海)股份有限公司 关于自愿披露 2025 年度经营业绩及 2026 年度经营业绩预测的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国证券法》《上市公司信息披露管理办法》《上海证券 交易所科创板股票上市规则》等有关规定,为让投资者更好地了解盛美半导体设 备(上海)股份有限公司(以下简称"公司")经营业绩情况,公司将2025年度 经营业绩及2026年度经营业绩预测公告如下: 一、2025年经营业绩情况 | 项目 | 2025 年 1 月 1 日–2025 | 年 | 12 月 | 31 日 | 上年同期 | | --- | --- | --- | --- | --- | --- | | 营业收入 | 668,000.00 万元–688,000.00 | | | 万元 | 561,774.04 万元 | | | 比上年同期增长: | | 18.91%–22.47% | | | 二、2025年经营业绩变动原因说明 ...
盛美上海(688082.SH):2025年公司营业收入66.8亿元-68.8亿元,比上年同期增长18.91%-22.47%
Ge Long Hui· 2026-01-22 10:29
综合近年来的业务发展趋势,以及目前的订单等多方面情况,公司预计2026年全年的营业收入将在人民 币82.00亿元至88.00亿元之间。 格隆汇1月22日丨盛美上海(688082.SH)公布,2025年1月1日-2025年12月31日公司营业收入66.8亿元-68.8 亿元,比上年同期增长18.91%-22.47%。 ...
盛美上海:预计2026年营业收入将在人民币82亿元至88亿元之间
Jin Rong Jie· 2026-01-22 10:29
Group 1 - The company expects its total revenue for the year 2026 to be between RMB 8.2 billion and RMB 8.8 billion [1] - For the year 2025, the company anticipates revenue to be between RMB 6.68 billion and RMB 6.88 billion, representing a year-on-year growth of 18.91% to 22.47% [1]
盛美上海:2025年营业收入同比预增18.91%—22.47%
人民财讯1月22日电,盛美上海(688082)1月22日公告,公司预计2025年营业收入为66.8亿元—68.8亿 元,比上年同期增长18.91%—22.47%。2025年全球半导体行业发展活跃,延续增长态势。公司凭借技 术差异化优势,成功把握市场机遇,积累了充足订单储备。公司销售交货及调试验收工作持续高效推 进,有效保障了经营业绩的稳步增长。 ...